Mo Miao, Tong Shiyu, Li Tao, Zu Xiongbing, Hu Xiheng
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, People's Republic of China.
Xiangya School of Medicine, Central South University, Changsha, Hunan 410008, People's Republic of China.
Onco Targets Ther. 2020 Aug 31;13:8757-8769. doi: 10.2147/OTT.S263980. eCollection 2020.
Chemokine (C-X-C motif) ligands (CXCLs) are important regulators of tumor progression in many cancers and could serve as potential cancer biomarkers. However, the expression patterns as well as functions of CXCLs remain unclear in penile cancer (PC). The aim of this study was to evaluate the usefulness of serum CXCL13 as a potential cancer biomarker for PC.
This retrospective study enrolled 76 patients diagnosed with PC between 2016 and 2018. Serum CXCL13 level was detected by enzyme-linked immunosorbent assay. Univariable and multivariable Cox regression analyses were conducted to identify the prognostic factors that influence disease-free survival. Human penile cancer cell lines Penl1, Penl2, 149RCa and LM156 were used as in vitro models. The expression of CXCL13 protein in PC cell lines was analyzed by Western blotting.
Our initial analysis on GSE57955 dataset identified CXCL13 as a top CXCL gene enriched in PC. Higher preoperative serum CXCL13 level was detected in PC cohorts than in healthy male controls (<0.001). The area under the curve was 0.911 with the sensitivity of 84.2% and specificity of 87.0% to distinguish PC. Preoperative serum CXCL13 level was associated with pathological grade (=0.048), T stage (=0.009), nodal status (<0.001) and pelvic lymph node metastasis (=0.005) in PC. Serum CXCL13 level could serve as an independent prognostic factor for disease-free survival with a HR of 3.818 (95%CI: 1.126-12.946). Furthermore, autocrine expression of CXCL13 was detected in PC tissues and cell lines. Knockdown of CXCL13 expression suppressed malignant phenotypes (cell proliferation, clonogenesis, apoptosis escape, migration and invasion), attenuated STAT3 and ERK1/2 signaling and reduced MMP2/9 secretion in PC cell lines.
Serum CXCL13 could serve as a novel diagnostic and prognostic biomarker for PC. CXCL13 signaling might activate oncogenic signaling pathways to promote malignant progression of PC.
趋化因子(C-X-C基序)配体(CXCLs)是许多癌症中肿瘤进展的重要调节因子,可作为潜在的癌症生物标志物。然而,CXCLs在阴茎癌(PC)中的表达模式和功能仍不清楚。本研究的目的是评估血清CXCL13作为PC潜在癌症生物标志物的效用。
这项回顾性研究纳入了2016年至2018年间诊断为PC的76例患者。采用酶联免疫吸附测定法检测血清CXCL13水平。进行单变量和多变量Cox回归分析以确定影响无病生存期的预后因素。用人阴茎癌细胞系Penl1、Penl2、149RCa和LM156作为体外模型。通过蛋白质印迹法分析PC细胞系中CXCL13蛋白的表达。
我们对GSE57955数据集的初步分析确定CXCL13是PC中富集的顶级CXCL基因。PC队列中术前血清CXCL13水平高于健康男性对照组(<0.001)。区分PC的曲线下面积为0.911,敏感性为84.2%,特异性为87.0%。PC患者术前血清CXCL13水平与病理分级(=0.048)、T分期(=0.009)、淋巴结状态(<0.001)和盆腔淋巴结转移(=0.005)相关。血清CXCL13水平可作为无病生存期的独立预后因素,风险比为3.818(95%置信区间:1.126-12.946)。此外,在PC组织和细胞系中检测到CXCL13的自分泌表达。CXCL13表达的敲低抑制了PC细胞系中的恶性表型(细胞增殖、克隆形成、凋亡逃逸、迁移和侵袭),减弱了STAT3和ERK1/2信号传导,并减少了MMP2/9的分泌。
血清CXCL13可作为PC的一种新型诊断和预后生物标志物。CXCL13信号传导可能激活致癌信号通路,促进PC的恶性进展。